Hyperkalemia in Patients with Type 2 Diabetes Mellitus: Risk Factors and Clinical Outcomes



Abstract Views
653

Downloads
455

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted May 21, 2023
Published Aug 31, 2023
10.24018/clinicmed.2023.4.4.291

Abstract viewed = 653 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Hyperkalemia is one of life-threatening electrolyte abnormalities. Diabetes mellitus (DM) is among the diseases in which patients can commonly develop hyperkalemia due to various factors. This study aimed to determine the occurrence of hyperkalemia and potential risk factors that contribute to development of hyperkalemia among type 2 diabetes mellitus (T2DM) patients. This is a single centered retrospective study in all deceased diabetic patients who were previously admitted to Sultan Ismail Petra Hospital, Kelantan state of Malaysia from January 2017 to December 2017 with or without hyperkalemia. A total of 132 patients were studied after screening for eligibility from medical records. Hyperkalemia was defined as potassium level ≥5.5 mEq/L. Univariate and multiple logistic regression analysis were used to identify potential risk factors associated with hyperkalemia. The occurrence of hyperkalemia among T2DM patients was 54.5%. In multivariable analysis, stage 4 CKD (eGFR: 15-29 ml/min/1.73m2) (AOR=0.154, 95%CI=0.003,0.763), use of ARB (AOR=26.269, 95%CI=1.25,548.50) and length of stay (AOR=1.007, 95%CI=1.001,1.013) were the significant risk factors for hyperkalemia. No significant difference between diabetes patients with hyperkalemia (DMHK) group with diabetes patients without hyperkalemia (DMWOHK) group in terms of clinical outcomes. Among diabetic patients with hyperkalemia, the mean time from development of hyperkalemia until death was 99.92±119.07 hours. In conclusion, this study shows that hyperkalemia is common among T2DM patient in our study setting. Although a number of factors may contribute to the high occurrence of hyperkalemia, the use of ARB, advanced CKD at stage 4 and length of stay are major determinants of hyperkalemia occurrence. Aggressive management of hyperkalemia may be beneficial as to prevent significant clinical outcomes requiring intensive care management and cardiac problem lead to death.

Keywords: ARB CKD diabetes mellitus hyperkalemia Malaysia

References

  1. Liamis G, Liberopoulos E, Barkas F, Elisaf M. Diabetes mellitus and electrolyte disorders. World Journal of Clinical Cases. 2014; 2(10): 488.
     Google Scholar
  2. An JN, Lee JP, Jeon HJ, Kim DH, Oh YK, Kim YS, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Critical Care. 2012; 16(6): 1-14.
     Google Scholar
  3. World Health Organization. Guideline: potassium intake for adults and children: World Health Organization; 2012.
     Google Scholar
  4. Uribarri J, Oh MS, Carroll H. Hyperkalemia in diabetes mellitus. Journal of Diabetic Complications. 1990; 4(1): 3-7.
     Google Scholar
  5. Jolobe O. Extreme hyperkalemia. Southern medical journal. 2006; 99(1): 96-7.
     Google Scholar
  6. National Kidney Foundation. Clinical Practice Guidelines For Chronic Kidney Disease: Evaluation, Classification and Stratification New York: National Kidney Foundation [Internet] 2002. Available from: https://www.kidney.org/sites/default/files/docs/ckd_evaluation_classification_stratification.pdf.
     Google Scholar
  7. Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. American Journal of Nephrology. 2017; 46(3): 213-21.
     Google Scholar
  8. Loutradis C, Tolika P, Skodra A, Avdelidou A, Sarafidis PA. Prevalence of hyperkalemia in diabetic and non-diabetic patients with chronic kidney disease: a nested case-control study. American Journal of Nephrology. 2015; 42(5): 351-60.
     Google Scholar
  9. Feisul M, Azmi S. National Diabetes Registry Report, Volume 1, 2009–2012. Kuala Lumpur: Ministry of Health, Malaysia; 2013.
     Google Scholar
  10. Awang H, Ja'afar SM, Wan Ishak NA, Zainal MY, Mohamed Aminuddin AM, Dollah Z. Poor Glycemic Control: Prevalence and Risk Factors Among Patients with Type 2 Diabetes Mellitus in Northeast State of Peninsular Malaysia. International Journal of Human and Health Sciences. 2020; 4(3): 206-14.
     Google Scholar
  11. Awang H, Muda R, Rusli N, Abd Rahman MA, Embong K. Epidemiology of Poor Glycaemic Control among Patients with Type 2 Diabetes Mellitus in Terengganu State of Malaysia. European Journal of Medical Health Sciences. 2022;4(5): 89-94.
     Google Scholar
  12. Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. Journal of General Internal Medicine. 2010; 25:3 26-33.
     Google Scholar
  13. Dittrich KL, Walls RM. Hyperkalemia: ECG manifestations and clinical considerations. The Journal of Emergency Medicine. 1986; 4(6): 449-55.
     Google Scholar
  14. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Texas Heart Institute Journal. 2006; 33(1): 40.
     Google Scholar
  15. Park S, Baek SH, Lee SW, Lee A, Chin HJ, Na KY, et al. Elevated baseline potassium level within reference range is associated with worse clinical outcomes in hospitalised patients. Scientific Reports. 2017; 7(1): 2402.
     Google Scholar
  16. Ab Aziz MI, Awang H. Comparison of International Normalized Ratio (INR) Between Point of Care Device Coaguchek® XS Versus Standard Laboratory Instrument Among Patients Receiving Warfarin Therapy In A Northeast State Of Peninsular Malaysia. International Journal of Public Health Clinical Sciences. 2019; 6(2): 215-28.
     Google Scholar
  17. Abidin TNTZ, Mustapa NNYN, Abdullah A, Ab Rahman NA, Ab Aziz MI, Awang H. Association of INR Quality With Complications Among Patients On Warfarin Therapy In Hospital Sultan Ismail Petra, Kelantan State. International Journal of Public Health Clinical Sciences. 2020; 7(1): 1-12.
     Google Scholar
  18. Raosoft I. Sample size calculator. [Internet] 2004. Available from: http://www.raosoft.com/samplesize.html.
     Google Scholar
  19. Ramadan F, Masoodi N, El‐Solh A. Clinical factors associated with hyperkalemia in patients with congestive heart failure 1. Journal of Clinical Pharmacy Therapeutics. 2005; 30(3): 233-9.
     Google Scholar
  20. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clinical Journal of the American Society of Nephrology. 2012; 7(8): 1234-41.
     Google Scholar
  21. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. The American Journal of Cardiology. 2012; 109(10): 1510-3.
     Google Scholar
  22. Jarman P, Kehely A, Mather H. Hyperkalaemia in diabetes: prevalence and associations. Postgraduate Medical Journal. 1995; 71(839): 551-2.
     Google Scholar
  23. Martín-Pérez M, Ruigómez A, Michel A, García Rodríguez LA. Impact of hyperkalaemia definition on incidence assessment: implications for epidemiological research based on a large cohort study in newly diagnosed heart failure patients in primary care. BMC Family Practice. 2016; 17(1): 1-8.
     Google Scholar
  24. Grodzinsky A, Goyal A, Gosch K, McCullough PA, Fonarow GC, Mebazaa A, et al. Prevalence and prognosis of hyperkalemia in patients with acute myocardial infarction. The American Journal of Medicine. 2016; 129(8): 858-65.
     Google Scholar
  25. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. Journal of the American College of Cardiology. 2007; 50(20): 1959-66.
     Google Scholar
  26. Thomsen R, Nicolaisen S, Adelborg K, Svensson E, Hasvold P, Palaka E, et al. Hyperkalaemia in people with diabetes: occurrence, risk factors and outcomes in a Danish population‐based cohort study. Diabetic Medicine. 2018; 35(8): 1051-60.
     Google Scholar
  27. Milionis HJ, Dimos G, Elisaf MS. Severe hyperkalaemia in association with diabetic ketoacidosis in a patient presenting with severe generalized muscle weakness. Nephrology Dialysis Transplantation. 2003; 18(1): 198-200.
     Google Scholar
  28. Kovesdy CP. Epidemiology of hyperkalemia: an update. Kidney International Supplements. 2016; 6(1): 3-6.
     Google Scholar
  29. Drion I, Joosten H, Dikkeschei L, Groenier K, Bilo H. eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. European Journal of Internal Medicine. 2009; 20(7): 722-7.
     Google Scholar
  30. Elgendy IY, Huo T, Chik V, Pepine CJ, Bavry AA. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. American Journal of Hypertension. 2015; 28(5): 576-85.
     Google Scholar
  31. Takaichi K, Takemoto F, Ubara Y, Mori Y. Analysis of factors causing hyperkalemia. Internal Medicine. 2007; 46(12): 823-9.
     Google Scholar
  32. Lee JW. Fluid and electrolyte disturbances in critically ill patients. Electrolytes. 2010; 8(2):72.
     Google Scholar
  33. Zhao G-j, Li D, Zhao Q, Song J-x, Chen X-r, Hong G-l, et al. Incidence, risk factors and impact on outcomes of secondary infection in patients with septic shock: an 8-year retrospective study. Scientific Reports. 2016; 6(1): 38361.
     Google Scholar
  34. Jeon CY, Neidell M, Jia H, Sinisi M, Larson E. On the role of length of stay in healthcare-associated bloodstream infection. Infection Control. 2012; 33(12): 1213-8.
     Google Scholar
  35. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian journal of endocrinology. 2012; 16(Suppl1): S27.
     Google Scholar
  36. Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug safety. 2014; 37: 677-92.
     Google Scholar
  37. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole–induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Archives of Internal Medicine. 2010; 170(12): 1045-9.
     Google Scholar
  38. Weir MA, Juurlink DN, Gomes T, Mamdani M, Hackam DG, Jain AK, et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clinical Journal of the American Society of Nephrology. 2010; 5(9): 1544-51.
     Google Scholar
  39. Kallen AJ, Welch HG, Sirovich BE. Current antibiotic therapy for isolated urinary tract infections in women. Archives of Internal Medicine. 2006; 166(6): 635-9.
     Google Scholar
  40. Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Annals of Internal Medicine. 1995; 122(2): 103-6.
     Google Scholar
  41. Gilbert DN. The Sanford guide to antimicrobial therapy: BI Publications Pvt Ltd; 2006.
     Google Scholar
  42. Baek J-E, Jung E-Y, Kim H-J, Lee G-W, Hahm J-R, Kang K-R, et al. Stenotrophomonas maltophilia infection in patients receiving continuous ambulatory peritoneal dialysis. The Korean Journal of Internal Medicine. 2004; 19(2): 104.
     Google Scholar
  43. Thiele A, Rehman HU. Hyperkalemia caused by penicillin. The American Journal of Medicine. 2008; 121(8): e1-e2.
     Google Scholar
  44. Groeneveld S, Verweij PE, Van't Hek L, Bökkerink JP, Warris A. Amphotericin B-deoxycholate overdose due to administration error in pediatric patients. Medical Mycology. 2008; 46(2): 185-7.
     Google Scholar
  45. Agarwal G, Singh SK. Arrhythmias in type 2 diabetes mellitus. Indian Journal of Endocrinology. 2017; 21(5): 715.
     Google Scholar
  46. Khanagavi J, Gupta T, Aronow W, Shah T, Garg J, Ahn C, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Archives of Medical Science. 2014; 10(2): 251-7.
     Google Scholar
  47. McMahon GM, Mendu ML, Gibbons FK, Christopher KB. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Medicine. 2012; 38: 1834-42.
     Google Scholar
  48. López-Vilella R, Morillas-Climent H, Plaza-Lopez D, Cebrian-Pinar M, Sanchez-Lazaro I, Almenar-Bonet L. Hyperkalemia in heart failure patients: current challenges and future prospects. Research Reports in Clinical Cardiology. 2016; 7: 1-8.
     Google Scholar
  49. Ishak NAW, Awang H, Abd Aziz R, Abdullah AJ, Bahari N. Prevalence and Determinants For Insulin Therapy Refusal Among Type 2 Diabetes Mellitus Patients In Primary Healthcare Facilities In East Coast Region Of Peninsular Malaysia. International Journal of Public Health and Clinical Sciences. 2019; 6(2): 160-71.
     Google Scholar
  50. Awang H, Ja'afar SM. Clinical Parameters Associated With Poor Glycaemic Control Among Type 2 Diabetes Mellitus Patients In Kelantan Setting. International Journal of Public Health and Clinical Sciences. 2020; 7(1): 25-34.
     Google Scholar
  51. Dokken BB. The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids. Diabetes spectrum. 2008; 21(3): 160-5.
     Google Scholar
  52. Rafique Z, Kosiborod M, Clark CL, Singer AJ, Turner S, Miller J, et al. Study design of Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): a multicenter, prospective, observational study. Clinical Experimental Emergency Medicine. 2017; 4(3): 154.
     Google Scholar
  53. Conway R, Creagh D, Byrne DG, O’Riordan D, Silke B. Serum potassium levels as an outcome determinant in acute medical admissions. Clinical Medicine. 2015; 15(3): 239.
     Google Scholar
  54. Einhorn LM, Zhan M, Walker LD, Moen MF, Seliger SL, Weir MR, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Archives of internal medicine. 2009; 169(12): 1156-62.
     Google Scholar